340
Participants
Start Date
July 22, 2022
Primary Completion Date
April 4, 2023
Study Completion Date
April 4, 2023
Varenicline Tartrate Nasal Spray
Intranasal delivery of OC-01 (varenicline solution) 0.6 mg/mL twice a day (BID) for 28 days
Placebo (vehicle)
Intranasal delivery of placebo (vehicle) twice a day (BID) for 28 days
Beijing Tongren Hospital, Beijing
The Second Hospital of Anhui Medical University, Hefei
Beijing Hospital, Beijing
Peking University Third Hospital, Beijing
Zhujiang Hospital of Southern Medical University, Guangzhou
The Affiliated Hospital of Guizhou Medical University, Guiyang
Shijiazhuang People's Hospital, Shijiazhuang
Hebei Eye Hospital, Xingtai
The First Affiliated Hospital of Harbin Medical University, Harbin
Henan Eye Hospital, Zhengzhou
Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan
Wuhan Aier Eye Hospital Hankou Hospital, Wuhan
Nanjing First Hospital, Nanjing
The First Bethune Hospital of Jilin University, Changchun
Eye Hospital of Shandong First Medical University, Jinan
Weifang Eye Hospital, Weifang
Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai
Tongji Hospital of Tongji University, Shanghai
Tianjin Medical University Eye Hospital, Tianjin
The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou
Lead Sponsor
Collaborators (1)
Oyster Point Pharma, Inc.
INDUSTRY
Corxel Pharmaceuticals
INDUSTRY